Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Verrica Pharmaceuticals (VRCA) Net Margin (2021 - 2025)

Verrica Pharmaceuticals (VRCA) has 5 years of Net Margin data on record, last reported at 163.02% in Q4 2025.

  • For Q4 2025, Net Margin fell 58421.0% year-over-year to 163.02%; the TTM value through Dec 2025 reached 51.72%, up 92520.0%, while the annual FY2025 figure was 53.4%, 92352.0% up from the prior year.
  • Net Margin reached 163.02% in Q4 2025 per VRCA's latest filing, down from 2.15% in the prior quarter.
  • Across five years, Net Margin topped out at 421.19% in Q4 2024 and bottomed at 17808.11% in Q1 2023.
  • Average Net Margin over 5 years is 2555.96%, with a median of 531.1% recorded in 2024.
  • Peak YoY movement for Net Margin: crashed -1584291bps in 2023, then soared 1727701bps in 2024.
  • A 5-year view of Net Margin shows it stood at 7.8% in 2021, then plummeted by -110533bps to 8629.41% in 2022, then surged by 86bps to 1239.89% in 2023, then skyrocketed by 134bps to 421.19% in 2024, then plummeted by -139bps to 163.02% in 2025.
  • Per Business Quant database, its latest 3 readings for Net Margin were 163.02% in Q4 2025, 2.15% in Q3 2025, and 1.61% in Q2 2025.